Parkinson’s disease is defined by the slow, relentless spread of a misfolded protein called alpha-synuclein through the brain, a process that ultimately claims the dopamine-producing neurons that control movement. For years, researchers have known that fibrillar seeds of this protein travel between cells in a prion-like fashion, templating healthy copies of the protein into toxic aggregates. What has remained frustratingly unclear is exactly how these seeds gain entry into cells in the first place. A new study published in Acta Neuropathologica now provides compelling in vivo evidence that a single immune receptor, FcγRIIb, also known as CD32b, acts as a critical gateway for alpha-synuclein propagation, and that blocking this receptor with antibodies already in clinical development can dramatically suppress the formation of pathological protein deposits in the mouse brain.
The research, led by James M. Hennegan and colleagues at the University of Southampton, focused on Fc gamma receptor IIb, the only inhibitory member of the Fc gamma receptor family that is conserved across species. These receptors normally serve as molecular sentinels of the immune system, binding the Fc domain of IgG antibodies and calibrating immune cell responses through a balance of activating and inhibitory signals. FcγRIIb restrains immune activation via its immunoreceptor tyrosine-based inhibitory motif, or ITIM, which recruits intracellular phosphatases when engaged. Crucially, the receptor is not confined to the periphery. Previous work has documented its expression on both neuronal and microglial membranes within the central nervous system, particularly under conditions of proteopathic stress, and earlier in vitro studies had shown that fibrillar alpha-synuclein binds directly to FcγRIIb, triggering downstream SHP-1/2-c-Src signalling that facilitates the protein’s internalisation.
What remained unresolved was whether this receptor genuinely governs alpha-synuclein spread in a living brain, rather than merely in a culture dish. To answer this question, the team turned to the preformed fibril, or PFF, model of synucleinopathy, in which synthetic fibrils of recombinant human alpha-synuclein are injected into the dorsal striatum of mice. The fibrils, fragmented by sonication into particles smaller than 50 nanometres and validated by transmission electron microscopy and Thioflavin-T fluorimetry, seed the aggregation of the brain’s own alpha-synuclein, generating Lewy body-like pathology that spreads along anatomically connected circuits in a manner that closely mirrors the human disease. The researchers compared wild-type C57BL/6 mice with mice in which the Fcgr2b gene had been deleted, and confirmed at both the RNA and protein levels that the knockout abolished receptor expression in the brain and spleen without altering other Fc gamma receptor family members or the mice’s own production of alpha-synuclein.
The results were striking. In primary cortical neurons cultured from embryonic tissue, exposure to preformed fibrils produced abundant phosphorylated alpha-synuclein, the pathological modification found at serine 129 that defines Lewy bodies, in wild-type cultures. Neurons lacking FcγRII showed an 88 percent reduction in this pathological staining, with far fewer inclusions in both the cell bodies and the neuritic arbours. When the team moved into living animals, injecting fibrils unilaterally into the striatum, the difference was even more dramatic. Thirty days after injection, wild-type mice had already developed robust phosphorylated alpha-synuclein pathology in the ipsilateral substantia nigra pars compacta, whereas knockout mice showed a near-complete absence of staining. By ninety days, wild-type brains were riddled with inclusions across the prefrontal cortex, primary motor cortex, entorhinal cortex, amygdala and substantia nigra, with muted deposition appearing even in the contralateral hemisphere, consistent with trans-hemispheric propagation.
The knockout mice were largely spared this anatomical cascade. Quantitative image analysis revealed reductions in pathological burden ranging from more than 70 percent in the ipsilateral substantia nigra to nearly 99 percent in the prefrontal and motor cortices, indicating that the receptor is not merely permissive but fundamental for efficient seeding and trans-neuronal propagation of the pathology along synaptically connected pathways. Distribution maps generated from the immunohistochemical data visualised the stark divergence between the two genotypes, with the wild-type hemisphere dotted with pathological signal and the knockout hemisphere almost clean. Control injections of monomeric, non-fibrillar alpha-synuclein produced no pathology in either genotype, confirming the specificity of the fibril-seeding response.
The protective effect extended beyond protein aggregation to the neurons themselves. Neuroinflammation is a central component of Parkinson’s pathogenesis, and in wild-type mice the fibril injection provoked a pronounced rise in microglial density, marked by increased Iba1 staining, and elevated expression of FcγRI, the high-affinity IgG receptor that appears on activated microglia. In knockout mice, this response was substantially blunted, with roughly a 72 percent reduction in Iba1-positive microglial density and a 29 percent decrease in FcγRI expression in the injected striatum at ninety days. The authors interpret this dampened gliosis as a secondary consequence of the reduced alpha-synuclein burden, suggesting that the receptor’s primary contribution to disease may be neuron-intrinsic, with impaired fibril internalisation limiting the downstream activation of glial cells.
Most importantly from a therapeutic standpoint, the loss of FcγRII preserved the nigrostriatal dopaminergic system. Wild-type mice injected with fibrils showed a marked reduction in tyrosine hydroxylase-positive fibre density in the dorsal striatum and a significant loss of dopamine neuron cell bodies in the substantia nigra by ninety days, the classic signature of progressive neurodegeneration in this model. Knockout mice maintained fibre density and neuronal counts equivalent to monomer-injected controls at both time points. Behavioural testing, conducted monthly before the animals were killed, suggested functional correlates of this protection: wild-type fibril-injected mice displayed reduced locomotor activity and exploratory drive in the open field and increased descent latency in the pole test, while knockout mice performed normally across all paradigms. The authors caution that the small cohort sizes render these behavioural findings suggestive rather than definitive, but their directionality aligns with the histological preservation.
To translate these genetic findings into a pharmacological strategy, the team exploited transgenic mice expressing human FcγRIIb and tested two monoclonal antibodies, BI-1206 and BI-1607, that selectively antagonise the human receptor. One antibody carried a wild-type Fc domain, while the other incorporated an N297Q substitution rendering it Fc-null, allowing the researchers to distinguish effects of receptor blockade itself from those mediated by Fc-driven engagement of activating Fc gamma receptors on immune cells. The antibodies were co-injected intracranially with the fibrils and supplemented with systemic dosing at 10 milligrams per kilogram to maintain circulating levels. Thirty days later, both antibody formats had produced a roughly 90 percent decrease in phosphorylated alpha-synuclein burden in the striatum and substantia nigra relative to an isotype control, with comparable efficacy between the Fc-wild-type and Fc-null variants. This equivalence suggests that blockade works predominantly through steric interference with the fibril-binding interface on the receptor, preventing alpha-synuclein uptake and pathological templating at the injection site before spread can begin.
The implications reach well beyond the laboratory. The antibodies used in this study are already advancing through oncology clinical trials, where FcγRIIb-directed therapeutics are being evaluated in CD32b-positive B-cell lymphomas, establishing a safety, tolerability and pharmacodynamic footprint that could accelerate repurposing toward neurodegenerative indications. Because the strategy targets the cellular entry route for fibrils rather than the protein aggregates themselves, it offers a mechanistically distinct complement to conventional anti-alpha-synuclein immunotherapies, which have struggled in clinical trials. Other receptors implicated in alpha-synuclein uptake, including LAG3, APLP1, the alpha-3 subunit of the sodium-potassium ATPase and connexin 32, suggest that fibrils may engage multiple overlapping entry pathways, but the magnitude of protection seen here indicates FcγRIIb is an especially influential conduit.
The authors are careful to note the limitations of the work. The initial knockout experiments used only male animals, cohort sizes were small, and tyrosine hydroxylase staining alone cannot distinguish frank neuronal loss from reduced expression or dysfunction without an independent pan-neuronal counterstain. The prophylactic antibody paradigm also does not address therapeutic intervention once pathology is established, and intracerebral delivery does not recapitulate the pharmacokinetics of systemic administration. Nevertheless, the convergence of genetic deletion and antibody blockade on the same outcome, a profound impairment of alpha-synuclein seeding, propagation and neurotoxicity in vivo, marks FcγRIIb as a pivotal and druggable regulator of synucleinopathy, and raises the tangible prospect that a receptor once studied for its role in immune regulation and cancer immunotherapy may become a target for slowing the progression of Parkinson’s disease.
Subject of Research: The role of the FcγRIIb receptor in alpha-synuclein propagation and its blockade as a therapeutic strategy for Parkinson’s disease
Article Title: Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo
Article References: Hennegan, J. M., Hurley, M. J., Colley, M., Cox, K. L., Douglas, L. R., Duriez, P. J., Oldham, R. J., Cragg, M. S., Frendéus, B., Roghanian, A., & Teeling, J. L. (2026). Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo. Acta Neuropathologica, 152(1), Article 40. https://doi.org/10.1007/s00401-026-03082-7
Image Credits: AI Generated
DOI: 10.1007/s00401-026-03082-7
Keywords: Parkinson’s disease, alpha-synuclein, FcγRIIb, CD32b, preformed fibrils, neurodegeneration, monoclonal antibodies, microglia, substantia nigra, prion-like propagation, immunotherapy, synucleinopathy
Cite Scienmag News
APA MLA Chicago
Diana Fleming. (September 25, 2026). Immune Receptor FcγRIIb Emerges as Gatekeeper of Parkinson’s Protein Spread. Scienmag. https://scienmag.com/immune-receptor-fc%ce%b3riib-emerges-as-gatekeeper-of-parkinsons-protein-spread/
Diana Fleming. “Immune Receptor FcγRIIb Emerges as Gatekeeper of Parkinson’s Protein Spread.” Scienmag, 25 September 2026, https://scienmag.com/immune-receptor-fc%ce%b3riib-emerges-as-gatekeeper-of-parkinsons-protein-spread/. Accessed 25 September 2026.
Diana Fleming. “Immune Receptor FcγRIIb Emerges as Gatekeeper of Parkinson’s Protein Spread.” Scienmag. September 25, 2026. https://scienmag.com/immune-receptor-fc%ce%b3riib-emerges-as-gatekeeper-of-parkinsons-protein-spread/
Copy citation Download RIS
Tags: alpha-synucleinalpha-synuclein spreadantibody blocking of FcγRIIbantibody-based therapy for neurodegenerative diseasesCD32bFcγRIIbFcγRIIb as cellular gatewayimmune modulation in Parkinson’simmune receptors in neurodegenerationimmune system’s impact on neurodegenerative progressionImmunotherapyinhibition of pathological protein depositsmicrogliamonoclonal antibodiesneurodegenerationParkinson’s diseasepreformed fibrilsprion-like propagationprion-like protein transmissionrole of immune receptors in protein aggregationsubstantia nigrasynucleinopathytherapeutic targets for Parkinson’s disease
